Evaluation of subvisible particles in human immunoglobulin and lipid nanoparticles repackaged from a multi-dose vial using plastic syringes

Int J Biol Macromol. 2023 Mar 31:232:123439. doi: 10.1016/j.ijbiomac.2023.123439. Epub 2023 Jan 27.

Abstract

The multi-dose vial (MDV) is widely used for most biopharmaceuticals that are repackaged in plastic syringes before use. However, subvisible particle formation with the use of plastic syringes containing silicone oil (SO syringes) for handling therapeutic proteins can be problematic. This study aimed to evaluate the extent of and trends in microparticle (>1 μm) formation and accumulation in repackaged syringes from MDVs containing human immunoglobulin (IgG) and lipid nanoparticles (LNPs). Light obscuration (LO) and flow imaging (FI) were used to analyze the microparticles. The number of microparticles observed with the use SO syringes was greater than that with SO-free syringes, and the number of microparticles continuously increased as did the number of times of repackaging in syringes for both drugs. However, a large variation was observed across different brands of SO syringes. In contrast, using a different technique of drug withdrawal from the vial significantly reduced the number of microparticles. Furthermore, the use of filter-integrated needles or the inclusion of stabilizers such as acetyl-arginine and Tween 20 into the formulation also helped reduce particle formation.

Keywords: Flow imaging; Multi-dose vial; Plastic syringe; Protein aggregation; Silicone oil; Subvisible particles.

MeSH terms

  • Bevacizumab
  • Humans
  • Immunoglobulins*
  • Plastics
  • Syringes*

Substances

  • Lipid Nanoparticles
  • Bevacizumab
  • Immunoglobulins
  • Plastics